Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
The costs of using a new class of cancer treatments include far more than the drugās sticker price.
The independent source for health policy research, polling, and news.
721 - 740 of 829 Results
The costs of using a new class of cancer treatments include far more than the drugās sticker price.
Moms-to-be in labor had to be evacuated from Santa Rosa hospitals in the midst of the California wildfires.
The harmful effects of all those hours on Facebook, Twitter and Instagram are well-documented. But lesser-known research shows that social media use may also provide mental health benefits.
California is one of only a handful of states nationwide that screens babies for the gene mutation that causes a rare brain disease ā a test that dramatically increases a sick childās chances of survival.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times, and Joanne Kenen of Politico discuss Congressā tardiness in renewing the Childrenās Health Insurance Plan (CHIP), and play the parlor game of who might become the new secretary of Health and Human Services. Also, the pod panel interviews Rep. John Larson (D-Conn.) about his new Medicare buy-in bill.
Federal funding for the Childrenās Health Insurance Program expired Sept. 30. Many states still have money in their budgets, but theyāll be worried until Congress renews the program.
Some teens and young adults are spending weeks or even months in retrofitted emergency rooms ā even in mesh-covered tents ā until specialized care can be found. āItās a huge problem,ā one doctor says.
In this Facebook Live, KHN's Julie Rovner talks to Bruce Lesley, president of First Focus, about the current state of play on CHIP reauthorization.
A shift in dental guidelines encourages first dental visits for infants as young as 6 months, or when the first baby teeth emerge. That makes some dentists uncomfortable.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of āorphan drugsā while closing a loophole that allowed drugmakers to skip pediatric testing.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Stephanie Armour of The Wall Street Journal discuss Democratic, Republican and bipartisan health proposals all being pursued in Congress, including the latest version of Sen. Bernie Sandersā (I-Vt.) āMedicare-for-Allā proposal. Plus, for āextra credit,ā the panelists recommend their favorite health stories of the week.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Mary Agnes Carey of Kaiser Health News discuss the return of Congress and bipartisan efforts to shore up the individual health insurance market for 2018, as well as renew the Childrenās Health Insurance Program.
This immunization may mark a shift among some vaccine makers to higher-priced, ānicheā preventives that protect against very specific and sometimes rare illnesses.
The Senate Finance Committee begins hearings Thursday on the program, which provides coverage to more than 9 million children and is up for renewal on Sept. 30.
New research offers evidence that coverage expansion policies for adults have a positive spillover effect for kids.
State lawmakers in California have an answer: legislation that would require your new insurer to keep paying for your current doctors even if theyāre not in the network.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Margot Sanger-Katz of The New York Times discuss the continuing efforts in Congress to ārepeal and replaceā the Affordable Care Act, upcoming open enrollment for individual insurance and Congressā long health care to-do list for September.
A program that provides $400 million in federal funding for the visits expires next month. Advocates and providers hope it will be reauthorized with a higher level of funding ā but some worry that might not happen.
One Kentucky program is eyed by other jurisdictions as a way to get addicted parents into recovery and help them care for their children at home.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Ā© 2026 KFF